These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 9293911)

  • 1. Fighting nausea in the '90s: more and better anti-emetics can help.
    Saphir A
    J Natl Cancer Inst; 1997 Sep; 89(17):1252-5. PubMed ID: 9293911
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemotherapy-induced nausea and vomiting.
    Hesketh PJ
    N Engl J Med; 2008 Jun; 358(23):2482-94. PubMed ID: 18525044
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.
    Hartvig P
    J Oncol Pharm Pract; 2007 Mar; 13(1):57-8. PubMed ID: 17621570
    [No Abstract]   [Full Text] [Related]  

  • 4. Overview: oral granisetron (Kytril tablets) prophylaxis for chemotherapy-induced nausea and vomiting.
    Perez EA
    Semin Oncol; 1995 Aug; 22(4 Suppl 10):1-2. PubMed ID: 7570049
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevention of delayed emesis caused by chemotherapy.
    Harmon D; O'Brien B
    N Engl J Med; 2000 Sep; 343(12):889; author reply 889-90. PubMed ID: 11001695
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemotherapy-induced nausea and vomiting with special emphasis on metopimazine.
    Herrstedt J
    Dan Med Bull; 1998 Sep; 45(4):412-22. PubMed ID: 9777292
    [No Abstract]   [Full Text] [Related]  

  • 7. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
    Slabý J; Trnený M; Procházka B; Klener P
    Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ondansetron to prevent vomiting after cancer chemotherapy.
    Med Lett Drugs Ther; 1991 Jun; 33(847):63-4. PubMed ID: 1828531
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of dexamethasone with 5-HT3-receptor antagonists.
    Perez EA
    Oncology (Williston Park); 1996 Jan; 10(1):14. PubMed ID: 8924363
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
    Perez EA
    Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy.
    Sigsgaard T; Herrstedt J; Andersen LJ; Havsteen H; Langer SW; Kjaerbøl AG; Lund H; Kjaer M; Dombernowsky P
    Br J Cancer; 1999 May; 80(3-4):412-8. PubMed ID: 10408847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Always more "setrons": how many do we need?
    Aapro MS
    Support Care Cancer; 1997 Jan; 5(1):1-2. PubMed ID: 9010981
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms and management of nausea and emesis.
    Dicato M
    Oncology; 1996 Jun; 53 Suppl 1():1-3. PubMed ID: 8692544
    [No Abstract]   [Full Text] [Related]  

  • 16. Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.
    Hamadani M; Awab A; Chaudhary L; Tfayli A
    J Oncol Pharm Pract; 2006 Jun; 12(2):67-8. PubMed ID: 16984743
    [No Abstract]   [Full Text] [Related]  

  • 17. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting.
    Fedele P; Spina M; Valentini M; Collini D; Lucia C; Manicone M; Tirelli U
    Cancer; 1995 Aug; 76(3):535-6. PubMed ID: 8625142
    [No Abstract]   [Full Text] [Related]  

  • 18. Update on the management of chemotherapy-related nausea and vomiting: an emphasis on the new class of agents--neurokinin-1 receptor antagonists.
    Gralla R
    Clin Adv Hematol Oncol; 2006 Jul; 4(7):507-8. PubMed ID: 17147235
    [No Abstract]   [Full Text] [Related]  

  • 19. Ondansetron: a specific serotonin antagonist for the prevention of chemotherapy-induced vomiting.
    Kris MG
    Important Adv Oncol; 1994; ():165-77. PubMed ID: 8206488
    [No Abstract]   [Full Text] [Related]  

  • 20. [Chemotherapy-induced emesis and serotonin antagonists].
    Jantunen I; Johansson R
    Duodecim; 1991; 107(14):1112-5. PubMed ID: 1670506
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.